AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18634163
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg once daily for up to 36 weeks
Trial: 11148740
Drug: Neoadjuvant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and adjuvant alpha-blocker therapy
Trial: 2291755
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg t.i.d. for 3 days
Trial: 2291755
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg t.i.d. for 7 days
Trial: 6127747
Drug: Diazepam 15
RxNorm normalized name: diazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 15 mg
Trial: 31154681
Drug: Post-immersion rehydration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-immersion rehydration (RH) with 1 L of water
Trial: 28391147
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor training programme (daily perineal massage and pelvic floor exercises from 32 weeks of pregnancy until birth)
Trial: 26371518
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + hydroxychloroquine 200 mg
Trial: 23577913
Drug: Web-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based training on cognitive behavioral therapy (CBT) skills
Trial: 21443446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, n=5)
Trial: 8141105
Drug: ondansetron 1
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 1 mg three times per day for 3 days
Trial: 8141105
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg three times per day for 3 days
Trial: 8141105
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg three times per day for 3 days
Trial: 8141105
Drug: ondansetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (all doses)
Trial: 9422292
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg
Trial: 23810271
Drug: 3% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% lidocaine emulsion formulation (NOPAYNE™)
Trial: 23810271
Drug: 4% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% aqueous solution (Xylocaine™)
Trial: 23774308
Drug: Submucosal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submucosal administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Trial: 23774308
Drug: Detrusor administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Detrusor administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Trial: 23774308
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of submucosal vs detrusor administration
Trial: 19242624
Drug: Orthopaedic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopaedic manual therapy
Trial: 16983840
Drug: i.v. dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. dexamethasone 0.5 mg/kg
Trial: 9411419
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anti thyroglobulin antibodies (ATG)
Trial: 9411419
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anti thyroid microsomal antibodies (MAB)
Trial: 2891536
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ranitidine
Trial: 2567580
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ranitidine
Trial: 6130952
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg cimetidine
Trial: 30793466
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (halved doses of valsartan and benazepril)
Trial: 22357964
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro salicylate treatment
Trial: 20378005
Drug: NiOH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NiOH treatment
Trial: 10488254
Drug: Bier block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bier block solution with 2 mg of morphine sulfate
Trial: 7659265
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg die
Trial: 7659265
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg die
Trial: 2504119
Drug: Flecainide (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (0.15 mg/kg/h after a loading dose of 2 mg/kg)
Trial: 18543484
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository
Trial: 10753983
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (INR 2.0 to 3.0)
Trial: 14725326
Drug: 5-FU (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (1% cream)
Trial: 10890481
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion plus transesophageal atrial pacing (group 2, 17 patients)
Trial: 10890481
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (group 1, 19 patients)
Trial: 6422538
Drug: Cimetidine, 200
RxNorm normalized name: Cimetidine, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 200 mg four times daily
Trial: 373071
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg twice daily
Trial: 6422538
Drug: Oxmetidine, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxmetidine, 400 mg twice daily
Trial: 28125093
Drug: Untreated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated group (no L-T4 supplementation)
Trial: 10754619
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg/kg
Trial: 10754619
Drug: Rapacuronium 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.0 mg/kg
Trial: 24973911
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (CC) program for treating depression following CABG surgery
Trial: 17986908
Drug: Health Education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Education Control (SA) consisting of weekly workshops transitioning to monthly
Trial: 16617391
Drug: (123)I‐ioflupane administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (123)I‐ioflupane administration (110‐185 MBq/70 kg); thyroid blocking with 120 mg potassium iodide before and after injection.
Trial: 14551174
Drug: eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 50 mg qd (increased to 100 mg qd if needed)
Trial: 8793612
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP, n = 24)
Trial: 6791487
Drug: Verapamil 360
RxNorm normalized name: verapamil 360 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 360 mg daily
Trial: 31945300
Drug: Isoniazid 5
RxNorm normalized name: isoniazid 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 5 mg/kg daily for 7 days
Trial: 22483675
Drug: Dose-escalation to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation to the entire primary tumour (arm A)
Trial: 22483675
Drug: Dose-escalation to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation to the primary tumour (arm A)
Trial: 22483675
Drug: Dose-escalation to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation to the high FDG uptake region inside the primary tumour (arm B)
Trial: 22483675
Drug: Dose-escalation to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation to the boost region
Trial: 20211036
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enteral nutrition (EN) with parenteral nutrition (PN)
Trial: 20211036
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) alone
Trial: 18540460
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy with crystalloidal solutions
Trial: 18540460
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of crystalloidal solutions and a colloidal agent in a 1:1 ratio
Trial: 18540460
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy with physiological sodium chloride
Trial: 12125943
Drug: Combination ointment
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ointment (calcipotriol/betamethasone dipropionate)
Trial: 16911387
Drug: Ointment vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment vehicle
Trial: 8540720
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine twice a day
Trial: 8540720
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine twice a day
Trial: 1780078
Drug: Heparan sulfate
RxNorm normalized name: heparan sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparan sulfate (200 mg/die, 1 tablet in the morning and evening)
Trial: 6112387
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 81 mg aspirin taken 14 h preoperatively
Trial: 6112387
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 40 mg aspirin taken 14 h preoperatively
Trial: 6112387
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 300 mg aspirin
Trial: 6112387
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 40 mg aspirin
Trial: 28402747
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg orally
Trial: 28402747
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days)
Trial: 23175270
Drug: Conventional cytology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cytology (CC)
Trial: 21047620
Drug: Individually-tailored Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually-tailored Internet-based treatment for anxiety disorders over 10 weeks with online therapist guidance.
Trial: 8800399
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg/day)
Trial: 3917315
Drug: Methimazole 30
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole 30 mg + thyroxine 0.15 mg daily
Trial: 31513248
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of adjuvant oxaliplatin-based chemotherapy
Trial: 29849515
Drug: Community-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based occupational therapy program (6 weeks)
Trial: 26528636
Drug: Baseline galectin‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline galectin‐3 (≥17.8ng/mL)
Trial: 26528636
Drug: Baseline sST2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline sST2 (≥35.0ng/mL)
Trial: 15206646
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily
Trial: 15036568
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice daily
Trial: 7875811
Drug: Intraosseous (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous (IO) route for fluid infusion
Trial: 7875811
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) route for fluid infusion
Trial: 3345044
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release theophylline
Trial: 30968604
Drug: Cisplatin-paclitaxel (Cisplatin-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin-paclitaxel (Cisplatin-20 mg/m2; Paclitaxel-30 mg/m2 qw x 7)
Trial: 25387260
Drug: Weekly testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly testosterone administration (100 mg T enanthate, im injection, n = 5)
Trial: 25387260
Drug: Monthly testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly testosterone administration (alternating months of T and placebo, n = 7)
Trial: 26535126
Drug: Naloxegol 25
RxNorm normalized name: naloxegol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol 25 mg
Trial: 24238792
Drug: Naloxegol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol 150 mg
Trial: 15673998
Drug: Self-selected homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected homeopathic medicine
Trial: 15673998
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by homeopaths
Trial: 31302851
Drug: Guanxinning Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxinning Tablet (GXN), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Trial: 31302851
Drug: Placebo (Guanxinning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Guanxinning simulation tablets, mainly composed of lactose), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Trial: 30051690
Drug: Mindfulness-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based group training (8 sessions of 90 minutes each, twice a week for 1 month)
Trial: 26999528
Drug: Zero-profile implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero-profile implant (Zero-P)
Trial: 20187135
Drug: Combination etanercept-methotrexate
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination etanercept-methotrexate therapy (EM/EM group, n = 111)
Trial: 20187135
Drug: Etanercept monotherapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept monotherapy (EM/E group, n = 111)
Trial: 20187135
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (M/EM group, n = 90)
Trial: 20187135
Drug: Combination etanercept-methotrexate
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination etanercept-methotrexate therapy (EM/EM group)
Trial: 20187135
Drug: Etanercept monotherapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept monotherapy (EM/E group)
Trial: 18576924
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral administration of C. aurantium L. extracts and auricular acupressure
Trial: 7863967
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone or Warfarin alone
Trial: 1645768
Drug: Lisinopril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-40 mg once a day)
Trial: 1645768
Drug: Captopril (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-100 mg twice a day)
Trial: 26953758
Drug: 4-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day antibiotic therapy (n = 72)
Trial: 23253201
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment condition (control group).
Trial: 9527071
Drug: Ongoing daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing daily therapy of 50 mg aspirin and 400 mg dipyridamole
Trial: 2214100
Drug: Intrapleural instillation
RxNorm normalized name: Talc Powder for intrapleural instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural instillation of 1500 mg of tetracycline hydrochloride
Trial: 22336901
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Group A)
Trial: 22773165
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg JNJ-37822681 (twice daily for 13 doses)
Trial: 22773165
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of JNJ-37822681
Trial: 11294130
Drug: Fibre supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement (initial dose of 6 g and maintenance dose of 4 g)
Trial: 11294130
Drug: Fibre supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement and reduced energy intake
Trial: 8872406
Drug: Lidocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (3 mg/kg i.v.) with liminal stimulation (C)
Trial: 8872406
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups after completed series of treatments
Trial: 8872406
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups after four treatments
Trial: 1379054
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg once a day for 5 days
Trial: 30582246
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (SS) (control)
Trial: 23584593
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA 1 g/day
Trial: 19574865
Drug: Extended-release epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release epidural morphine (EREM) groups (with/without prior bupivacaine)
Trial: 19574865
Drug: Bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine + placebo (normal saline) administered 15, 30, or 60 mins after bupivacaine
Trial: 15121929
Drug: Prophylactic application
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic application of emollient ointment twice a day through day 14 (P)
Trial: 8075441
Drug: 0.5% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podophyllotoxin cream
Trial: 8003791
Drug: 0.3% and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% and 0.5% podophyllotoxin creams
Trial: 2523681
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nebulized solution 0.4 mg
Trial: 2523681
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nebulized solution 0.4 mg and 0.6 mg
Trial: 304691
Drug: Kallikrein inhibitor
RxNorm normalized name: Kallikrein inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallikrein inhibitor (protease-inhibitor)
Trial: 304691
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no kallikrein inhibitor)
Trial: 17189867
Drug: Rosiglitazone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone + Insulin